Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

TSUBASA Study: A Prospective Study Evaluating the Association between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

Keiji Nogami, Teruhisa Fujii, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano

Blood (2024) 144 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2024-193537

Published: 2024

Journal Articles

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Azusa Nagao, Keiji Nogami, Nobuaki Suzuki, Chiai Nagae, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2588.

https://doi.org/10.1182/blood-2024-193535

Published: 2024

Journal Articles

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Allison P. Wheeler, Aby Abraham, Chris Barnes, Renée Brown Frandsen, Kingsley Hampton, Francisco José López Jaime, Camila Martins Mazini Tavares, Keiji Nogami, Jerzy Windyga, Giancarlo Castaman

Blood (2024) 144 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2024-209752

Published: 2024

Journal Articles

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Robert Klamroth, Stephanie P'ng, Sophie Susen, Davide Matino, Pratima Chowdary, Angela C Weyand, Toshko Lissitchkov, Young-Shil Park, María Teresa Alvarez-Román, Liqi Feng, Helena Palmborg, Jennifer Dumont, Elena Santagostino, Lara Mamikonian, Keiji Nogami

Blood (2024) 144 (Supplement 1): 717.

https://doi.org/10.1182/blood-2024-204533

Published: 2024

Journal Articles

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

Azusa Nagao, Yusuke Inagaki, Keiji Nogami, Naoya Yamasaki, Fuminori Iwasaki, Yang Liu, Yoichi Murakami, Takahiro Ito, Hideyuki Takedani

Blood (2023) 142 (Supplement 1): 3645.

https://doi.org/10.1182/blood-2023-174054

Published: 2023

Journal Articles

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

Tadashi Matsushita, Nobuaki Suzuki, Chiai Nagae, Azusa Nagao, Masahiko Ando, Yachiyo Kuwatsuka, Daisuke Nosaka, Yui Kyogoku, Tomomi Shimura, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2023-173071

Published: 2023

Journal Articles

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman, Aby Abraham, Pantep Angchaisuksiri, Laura Villarreal Martinez, Keiji Nogami, Jameela Sathar, Chunduo Shen, Jay Jay Thaung Zaw, Guy Young

Blood (2023) 142 (Supplement 1): 284.

https://doi.org/10.1182/blood-2023-180790

Published: 2023

Journal Articles

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Shoko Furukawa, Masahiro Takeyama, Keiji Nogami

Blood (2023) 142 (Supplement 1): 2603.

https://doi.org/10.1182/blood-2023-174626

Published: 2023

Journal Articles

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Masahiro Takeyama, Tomoya Miyatake, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami

Blood (2023) 142 (Supplement 1): 5469.

https://doi.org/10.1182/blood-2023-174793

Published: 2023

Journal Articles

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Chiai Nagae, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Hiroki Oki, Keisuke Iwasaki, Keiji Nogami

Blood (2023) 142 (Supplement 1): 3991.

https://doi.org/10.1182/blood-2023-173073

Published: 2023

Journal Articles

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

Yoshiyuki Ogawa, Kagehiro Amano, Akiko Ioka, Daisuke Nosaka, Yoichi Murakami, Hiroki Adachi, Keiji Nogami

Blood (2022) 140 (Supplement 1): 5627–5628.

https://doi.org/10.1182/blood-2022-157170

Published: 2022

Journal Articles

Activated Protein C-Catalyzed Inactivation Pathway Down-Regulates NXT007-Mediated Hemostatic Function

Yuto Nakajima, Kenichi Ogiwara, Takehisa Kitazawa, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 5576–5577.

https://doi.org/10.1182/blood-2022-162928

Published: 2022

Journal Articles

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

Kuniyoshi Mizumachi, Yuto Nakajima, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2022) 140 (Supplement 1): 8430–8431.

https://doi.org/10.1182/blood-2022-165714

Published: 2022

Journal Articles

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Midori Shima, Hideyuki Takedani, Kaoru Kitsukawa, Masashi Taki, Akira Ishiguro, Azusa Nagao, Daisuke Nosaka, Yui Kyogoku, Keisuke Iwasaki, Keiji Nogami

Blood (2022) 140 (Supplement 1): 2742–2744.

https://doi.org/10.1182/blood-2022-157249

Published: 2022

Journal Articles

Suppressed Fibrinolytic Activity Demonstrated By Simultaneous Thrombin and Plasmin Generation Assay during Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy

Takashi Ishihara, Yasuyuki Arai, Makiko Morita, Tomoko Onishi, Hanako Shimo, Toshio Kitawaki, Akifumi Takaori-Kondo, Soichi Adachi, Keiji Nogami

Blood (2021) 138 (Supplement 1): 4807.

https://doi.org/10.1182/blood-2021-146311

Published: 2021

Journal Articles

Orihime Study: Real World Treatment Patterns and Clinical Outcomes of 338 Patients with Acquired Hemophilia a from a Japanese Health Claims Database

Yoshiyuki Ogawa, Kagehiro Amano, Yukari Matsuo-Tezuka, Norihiro Okada, Yoichi Murakami, Takao Nakamura, Haruko Yamaguchi-Suita, Keiji Nogami

Blood (2021) 138 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2021-146418

Published: 2021

Journal Articles

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Yuto Nakajima, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Masahiro Takeyama, Midori Shima, Keiji Nogami

Blood (2021) 138 (Supplement 1): 2100.

https://doi.org/10.1182/blood-2021-146337

Published: 2021

Journal Articles

Effects of Bypassing Hemostatic Agents in the Co-Presence of NXT007, Emicizumab-Based Engineered Bispecific Antibody to Fixa/Fx, Using in Vitro Global Assays: Rough Indicators for Their Concomitant Use

Kenichi Ogiwara, Shoko Furukawa, Kana Sasai, Keito Inaba, Takehisa Kitazawa, Keiji Nogami

Blood (2021) 138 (Supplement 1): 2114.

https://doi.org/10.1182/blood-2021-149412

Published: 2021

Journal Articles

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Midori Shima, MD, Sayaka Nagami, BSc, Koichiro Yoneyama, MSc, Akira Nomura, MSc, Yoshiyuki Ogawa, MD PhD, Kagehiro Amano, MD PhD, Keiji Nogami, MDPhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136488

Published: 2020

Journal Articles

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Yuto Nakajima, MD, Keiji Nogami, MD PhD, Hiroaki Minami, MD, Kana Sasai, Midori Shima, MD PhD

Blood (2019) 134 (Supplement_1): 1107.

https://doi.org/10.1182/blood-2019-129313

Published: 2019

NARROW

TSUBASA Study: A Prospective Study Evaluating the Association between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Research and Evaluation of the Diagnostic Precision of an Artificial Intelligence Algorithm Using Ultrasound Images for Early Diagnosis of Arthropathy in People with Hemophilia

AKATSUKI 48-Week Interim Analysis: Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Contribution of the Residues 488-490 on the Factor (F)VIII A2 Domain and the Residue 2239 on the FVIII C2 Domain for the Interaction between FVIII and Protein S

Impact of Anticoagulant Function By the Addition of Heparinoid in Vitro in the Plasmas from Patients with Hemophilia and Von Willebrand Disease

Three-Year Interim Analysis Results of the AOZORA Study to Evaluate the Long-Term Safety and Joint Health in Children with Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab

ORIHIME II Study: Background, Treatment Status, and Outcomes of Patients with Acquired Hemophilia A with Low Activities of Daily Living Scores or Undergoing Rehabilitation - a Japanese Health Claims Database Analysis

Activated Protein C-Catalyzed Inactivation Pathway Down-Regulates NXT007-Mediated Hemostatic Function

Escaping Ability of Human-Porcine Hybrid Factor VIII from Anti-Factor VIII Inhibitors with an A2 or C2 Epitope

AOZORA Study: Interim Analysis of Joint Health in Children with Hemophilia A, without FVIII Inhibitors, 3 Years after Initiating Emicizumab

Suppressed Fibrinolytic Activity Demonstrated By Simultaneous Thrombin and Plasmin Generation Assay during Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy

Orihime Study: Real World Treatment Patterns and Clinical Outcomes of 338 Patients with Acquired Hemophilia a from a Japanese Health Claims Database

Global Coagulation Potentials and Breakthrough Bleeds in Emicizumab-Treated Hemophilia a Patients Were Similar to Mild Hemophilia a Patients

Effects of Bypassing Hemostatic Agents in the Co-Presence of NXT007, Emicizumab-Based Engineered Bispecific Antibody to Fixa/Fx, Using in Vitro Global Assays: Rough Indicators for Their Concomitant Use

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Residues 1680-1684 in the A3 Domain of Factor VIII Contain a Novel Thrombin-Interactive Site Responsible for Proteolytic Cleavage at Arg 1689

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only